Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvucitabine Extension Study in HIV-1
NCT00380159Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of elvucitabine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety of Elvucitabine in Combination with ART at 48 weeks. Started Sep 2006; status: completed.
02
Drugs
elvucitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00380159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380159.